Andy Neely is Cambridge’s Pro-Vice-Chancellor for Enterprise and Business Relations, a role which oversees the University’s activities in innovation, commercialisation and entrepreneurship. After six months in the role, he sees an entrepreneurial ecosystem that may appear complex at first – but a deeper examination reveals a combination of knowledge, expertise, support and infrastructure that makes Cambridge one of the most enterprising and entrepreneurial cities in the world.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
Technology to improve the security, speed and scale of data processing in age of the Internet of Things is being developed by a Cambridge spin-out company.
Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge, has launched a film that showcases some of the world-changing ideas it has supported in the journey to market – from a drug with the potential to save millions of lives to a flower seed mix that helps bees.
A major showcase of companies developing new technologies from graphene and other two-dimensional materials took place this week at the Cambridge Graphene Centre.
Technology developed at the University of Cambridge lies at the heart of a commercial process that can turn toothpaste tubes and drinks pouches into both aluminium and fuel in just three minutes.